S-1/A: SRx Health Solutions Navigates Restructuring, Eyes Pet Wellness & AI Growth

SRx Health Solutions, Inc. is undergoing a significant business transformation, divesting its Canadian healthcare operations to focus on its Halo pet wellness brand and a proposed acquisition in AI and crypto technology, while facing substantial financial challenges and potential dilution.

Summary

• SRx Health Solutions, Inc. (formerly Better Choice Company Inc.) has transitioned its core business, discontinuing its Canadian specialty pharmaceuticals and healthcare services (SRx Canada) due to CCAA proceedings and focusing solely on its Halo pet health and wellness brand.
• The company reported net sales from continuing operations (Halo pet business) of $6.534 million for the year ended September 30, 2025, with a gross profit of $1.526 million (23% gross margin).
• A net loss from continuing operations of $8.639 million and an Adjusted EBITDA loss of $1.762 million were reported for the year ended September 30, 2025.
• Cash used in operating activities for continuing operations was $8.143 million for the year ended September 30, 2025.
• The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern, citing the need for additional capital.
• SRx Canada initiated restructuring proceedings under the Companies Creditors Arrangement Act (CCAA) in August 2025, leading to the sale or discontinuation of most of its assets and businesses.
• The company completed a reverse merger on April 24, 2025, with SRx Canada identified as the accounting acquirer, resulting in a preliminary bargain purchase gain of $4.1 million.
• A private placement on April 25, 2025, raised $8.8 million through the issuance of 4,036,697 common shares and pre-funded warrants.
• The company entered into a July PIPE Financing on July 7, 2025, issuing $7.65 million in senior secured convertible notes (8% interest, maturing July 8, 2027) and warrants for 21,338,062 common shares.
• An October PIPE Financing on October 27, 2025, involved the sale of 19,035 shares of Series A convertible preferred stock and 54,527,811 warrants for aggregate proceeds of $15.23 million, with $8.66 million in cash and the cancellation of July Notes/Warrants.
• The ELOC Purchase Agreement was amended on October 28, 2025, increasing the total commitment from $50 million to $1.0 billion, and a $20.0 million convertible promissory note was issued to the lead investor.
• A proposed acquisition of EMJ Crypto Technologies Inc. and CCC Crypto Corp. (EMJC Transaction) for approximately $55 million in stock, involving AI technology for predicting outcomes from data sets (including an algorithm designed to outperform Bitcoin and Ethereum), is subject to stockholder approval and other closing conditions.
• The company's common stock is listed on the NYSE American under the symbol SRXH, with a closing price of $0.31 per share on December 19, 2025.
• The company received a notice from NYSE American on October 14, 2025, regarding non-compliance with the continued listing standard for stockholders' equity below $4 million.
• The number of authorized common shares was increased from 200,000,000 to 5,000,000,000 on November 19, 2025.
• Up to 187,544,974 shares of common stock are being registered for resale by selling stockholders, representing approximately 7% of the total fully diluted outstanding common stock, but potential full dilution from all outstanding derivatives could reach 2,764,605,238 shares.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a going concern warning, recurring losses, negative operating cash flow, and NYSE American non-compliance. While there are efforts to restructure and raise capital, and a strategic shift to pet wellness and potential AI diversification, the immediate financial health and significant dilution risks present a highly unfavorable outlook.

Positives

• The company completed a reverse merger, streamlining its corporate structure and focusing on the Halo pet health and wellness business.
• The Halo pet health and wellness brand has a multi-decade track record of success and is well-positioned in the growing pet humanization and health trends.
• The company successfully raised $8.8 million in a private placement on April 25, 2025.
• The July PIPE Financing secured $7.65 million in senior secured convertible notes and warrants.
• The October PIPE Financing secured $15.23 million in proceeds from Series A preferred stock and warrants, with $8.66 million in cash.
• The ELOC Purchase Agreement commitment was significantly increased from $50 million to $1.0 billion, providing substantial potential future capital.
• A proposed acquisition of EMJ Crypto Technologies Inc. and CCC Crypto Corp. for $55 million in stock could diversify the business into AI and cryptocurrency technology.
• The company recorded a bargain purchase gain of $4.1 million from the reverse merger, indicating it acquired net assets at a discount.
• The company has a streamlined operating footprint and reduced overhead after discontinuing the capital-intensive SRx Canada healthcare operations.

Negatives

• The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company incurred a net loss from continuing operations of $8.639 million and an Adjusted EBITDA loss of $1.762 million for the year ended September 30, 2025.
• Cash used in operating activities for continuing operations was $8.143 million for the year ended September 30, 2025.
• SRx Canada, the former primary business, filed for CCAA protection and its operations have been discontinued, indicating significant past financial difficulties.
• The company received a notice from NYSE American on October 14, 2025, regarding non-compliance with the continued listing standard for stockholders' equity below $4 million.
• The market price of common stock was $0.31 per share on December 19, 2025, which is significantly lower than historical prices (e.g., $24.59 in Q1 2023).
• The potential resale of up to 187,544,974 shares by selling stockholders, representing approximately 7% of fully diluted shares, could cause significant market price decline and volatility.
• The fully diluted share count, including all warrants, options, and convertible securities, could reach 2,764,605,238 shares, indicating massive potential dilution for existing shareholders.
• The company has historically reported net losses and expects to continue generating operating losses and consuming cash resources in the near term.
• The company has limited direct operations and relies on its subsidiaries for cash flow, which could subordinate shareholder rights to subsidiary creditors in case of insolvency.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and need for additional capital.
• Inability to successfully implement growth strategy or effectively manage anticipated growth could adversely impact the business.
• Loss of key members of senior management team could negatively impact operations and profitability.
• Inability to generate sufficient cash flow or raise capital on acceptable terms to run operations, service debt, and make necessary capital expenditures.
• Dependence on subsidiaries for payments, advances, and transfers of funds due to holding company status.
• Inability to successfully develop additional products and services or successfully market and commercialize them.
• Intense competition in the pet health and wellness market from companies with greater resources.
• Vulnerability to fluctuations in the price and supply of key inputs, including ingredients, packaging materials, and freight.
• Food safety and food-borne illness incidents could lead to lawsuits, product recalls, regulatory actions, increased costs, and reduced demand.
• Adverse litigation judgments or settlements could materially adversely affect business, financial condition, and results of operations.
• Heavy reliance on third-party commerce platforms (e.g., Amazon, Chewy) means compromise of these platforms could harm the business.
• Risks associated with growth through acquisitions, investments, or strategic alliances, including integration problems and unanticipated costs.
• International expansion exposes the company to substantial business, regulatory, political, financial, and economic risks.
• Decreased spending on pets in a challenging economic climate could reduce demand for premium products.
• Significant merchandise returns or refunds could harm the business.
• Inadequate intellectual property rights may fail to protect the business.
• Failure of key information technology systems, networks, or processes could materially adversely affect the ability to conduct business.
• Failure to comply with the U.S. Foreign Corrupt Practices Act, other anti-corruption laws, and trade control laws could lead to penalties.
• Ability to utilize net operating loss carryforwards may be limited under Section 382 of the Code.
• Non-compliance with extensive governmental regulations (FDA, FTC, USDA) for animal food products could lead to enforcement actions, recalls, or penalties.
• Changes in existing laws or regulations, or adoption of new ones, may increase costs and adversely affect the business.
• Provisions in the certificate of incorporation and bylaws and Delaware law may discourage takeover attempts.
• The administrative and regulatory costs of public company compliance could consume significant resources.
• The common stock may be deemed a penny stock, adversely affecting its market price and liquidity.
• Failure to meet NYSE American continued listing requirements could result in delisting.
• The market price of common stock may be volatile due to various factors, including sales by affiliates.
• Future sales of common stock, or the perception of such sales, may depress the share price and dilute ownership.
• Issuance of preferred stock could adversely affect the voting power or value of common stock.
• The exclusive forum provisions in the bylaws may limit stockholders' ability to choose judicial forums for disputes.

Future Outlook

The company's outlook reflects the early stages of a business reset, with near-term priorities focused on strengthening the financial position of the continuing Halo pet wellness operations, optimizing cost structure, and re-establishing a focused growth path. Management believes the streamlined business provides a clearer path to operational stability and disciplined execution. The company will continue evaluating strategic alternatives, including potential partnerships, product expansion, and targeted investments aligned with the strengths of the continuing operations. The proposed EMJC Transaction aims to diversify into AI and cryptocurrency technology, subject to stockholder approval and other closing conditions.

Management Comments

• Management believes that the streamlined business provides a clearer path to operational stability and disciplined execution.
• Management believes it is in the company's best interests to have the flexibility to sell Common Shares pursuant to the ELOC Purchase Agreement, subject to market conditions.
• Management believes its overall relationships with its employees are positive and the strength of its team is a critical success factor in becoming the most innovative premium pet food company in the world.

Industry Context

The company is shifting its focus to the pet health and wellness industry, which benefits from mainstream trends of growing pet humanization and consumer focus on health and wellness. This industry is highly competitive, with numerous players ranging from large conventional pet food manufacturers to specialty and natural pet food brands. The company's strategy emphasizes digital-first distribution through e-commerce platforms like Amazon and Chewy, aligning with increasing consumer preference for online purchasing. The proposed acquisition into AI and cryptocurrency technology represents a significant diversification away from its historical healthcare and current pet wellness focus, potentially positioning it in emerging, high-growth tech sectors, though this move is highly speculative and distinct from its current operational expertise.

Comparison to Industry Standards

• Halo's premium and super-premium products (retail price greater than $0.20 per ounce) compete with established brands like Mars, Nestlé, Big Heart Pet Brands, Blue Buffalo (General Mills), Wellness, Fromm, Orijen, Merrick (Nestlé), Stella and Chewy, Open Farm, and Freshpet.
• Halo management believes it is better equipped to customize products for the pet health and wellness market compared to other companies, but faces competition from larger players with greater financial resources and longer operating histories.
• The company's gross margin of 23% for the year ended September 30, 2025, is subject to inflationary pressures on transportation and raw material costs, which is a common challenge across the consumer goods and pet food industries.
• The proposed EMJC Transaction, involving AI technology designed to outperform Bitcoin and Ethereum based on trading volatility, is a highly speculative venture that deviates significantly from the company's current industry focus and lacks direct comparable projects or results within its existing business segments.

Management Changes

Corporate Governance

Legal Proceedings

• SRx Canada, a wholly-owned subsidiary, filed for protection under the Companies Creditors Arrangement Act (CCAA) on August 11, 2025, leading to the classification of its operations as discontinued.
• The CCAA proceedings involved obtaining an Initial Order, granting a stay of proceedings, appointing a monitor (Grant Thornton Limited), granting debtor-in-possession financing (up to $1,750,000), and approving sale procedures for SRx Canada's assets and businesses.
• The Court approved transactions for the sale of substantially all of SRx Canada's assets and businesses on August 21, 2025, and October 29, 2025, with most sales completed.
• The current stay of proceedings for SRx Canada has been extended to January 30, 2026, to permit the completion of the restructuring.
• Neither the company nor its U.S. subsidiary, Halo, Purely For Pets, Inc., has made any filing under any bankruptcy code or statutory reorganization scheme.

Related Party Transactions

• As of September 30, 2025, the company had outstanding convertible promissory notes totaling $0.5 million held by certain members of the Board of Directors, bearing 8% interest per annum and convertible into common stock.
• For the fiscal year ended September 30, 2025, continuing operations incurred approximately $0.7 million in director fees, of which $0.5 million were settled in exchange for the convertible notes.
• During the year ended September 30, 2025, the company issued an aggregate of $3.2 million in share-based compensation to its directors and executive officers.
• During the period from July through September 2025, the company issued 2,987,477 shares of restricted common stock to certain directors, officers, employees, and former employees as performance or service-based compensation.
• On August 25, 2025, the company issued 2,396,697 shares of restricted common stock to certain directors, officers, and employees as performance bonus compensation, immediately vested at a weighted average grant price of $0.40 per share.
• On September 16, 2025, the company issued 196,000 shares of restricted common stock to certain current and former directors, immediately vested at a weighted average grant price of $0.35 per share.
• Between July and September 2025, the company issued 394,780 shares of common stock due to the retraction of exchangeable shares by former employees and shareholders of SRx Canada.
• Michael Young's beneficial ownership includes shares directly owned, indirectly held through Cottingham Capital, LLC, and shares issued to Halo Spin-out SPV, Inc., over which he has voting/investment power, though he disclaims beneficial ownership of the SPV shares.
• Simon Conway's beneficial ownership includes shares held indirectly through Matterhorn Capital.
• KCP Fund I, LLC, an affiliate of Keystone Capital Partners, LLC, is managed by RANZ Group LLC, and Fredric Zaino (Managing Member of RANZ Group LLC) may be deemed to have investment discretion and voting power over its shares, disclaiming beneficial ownership.

Stakeholder Impact

• **Shareholders:** Face significant potential dilution from the resale of 187.5 million shares by selling stockholders and the potential issuance of up to 2.5 billion shares under the ELOC agreement. The going concern warning and recurring losses pose a high risk to investment value. The proposed EMJC transaction could introduce new growth avenues but also new risks.
• **Employees:** The restructuring of SRx Canada led to the discontinuation of operations, likely impacting employees in that segment. The company's focus on the Halo pet wellness business and a 'Win From Anywhere' culture aims to attract and retain talent in the continuing operations.
• **Customers (Halo):** The strategic exit from certain brick-and-mortar retailers (Petco, Pet Supplies Plus) and the DTC channel, with a shift to Amazon and Chewy, changes how customers access Halo products. The focus on brand awareness and innovation aims to retain and attract new customers.
• **Suppliers/Co-manufacturers:** The company relies on a limited number of third-party suppliers and co-manufacturers, making it vulnerable to supply chain disruptions, price fluctuations, and compliance issues. Maintaining these relationships is critical for product availability.
• **Creditors:** The CCAA proceedings for SRx Canada directly impact creditors of that subsidiary. The company's overall indebtedness and going concern status present risks to creditors of the continuing operations, although recent PIPE financings and the ELOC provide capital infusions.

Next Steps

• Selling stockholders may resell up to 187,544,974 shares of common stock from time to time.
• The company needs to obtain stockholder approval for the EMJC Transaction.
• The company needs to file and mail a definitive information statement with the SEC for the EMJC Transaction.
• The shares of common stock to be issued in the EMJC Transaction must be approved for listing on the NYSE American.
• The company will file an S-4 Registration Statement for the resale of common shares issued in the EMJC Transaction.
• The company must perform its obligations under the Transfer Agreement for the EMJC Transaction to close.
• The company intends to regain compliance with NYSE American continued listing standards by July 14, 2026.
• The current stay of proceedings for SRx Canada is extended to January 30, 2026, to complete restructuring.
• The company will continue evaluating strategic alternatives to support the long-term viability of the business, including potential partnerships, product expansion opportunities, and targeted investments.
• The company will continue to work with co-manufacturing and freight partners to realize future cost savings and improved gross margins.
• The company will continue to refine and optimize its pricing strategy to align with market conditions and manage cost pressures.
• The company will continue to evaluate both positive and negative evidence each reporting period to determine whether a release of the valuation allowance for deferred tax assets is warranted.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, marked by a 'going concern' warning from auditors, recurring net losses, and negative operating cash flow. The discontinuation of its former primary business (SRx Canada) due to creditor protection underscores past failures. While the company is attempting a pivot to pet wellness and a highly speculative AI/crypto venture, the massive potential for shareholder dilution (up to 2.7 billion fully diluted shares compared to 69.5 million currently outstanding) from various financing activities, coupled with a low stock price ($0.31) and NYSE American non-compliance, presents an extremely high-risk profile. The proposed EMJC transaction, while potentially transformative, introduces significant execution risk in an entirely new, volatile sector. For a seasoned investor, the overwhelming financial risks, dilution, and uncertainty surrounding the business transformation make this a 'strong sell' to avoid further capital erosion.

Keywords

Pet Health, Pet Wellness, Halo Brand, SEC Filing, S-1/A, Going Concern, Capital Raise, Dilution, Convertible Notes, Warrants, Private Placement, Reverse Merger, CCAA, Restructuring, AI Technology, Cryptocurrency, NYSE American, Smaller Reporting Company, Corporate Governance, Risk Factors